Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?

References (5)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines fort he management of patients with atrial fibrillation-executive summary. Eur Heart J 2006; 27: 1979-2030
2. Selcuk H, Selcuk MT, Maden O. Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi? Anadolu Kardiyol Derg 2007; 7: 54-8
3. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized controlled trial. Lancet 2003; 362: 1691-8
4. Albers GW, Diener HC, Frison l, Grind M, Nevinson M, Partridge S, et al. SPORTIF Executive Steering Committee fort he SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-8
5. O’Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005; 293: 699-706.